Fresenius Kabi received Health Canada's Notice of Compliance (NOC) approval for Iodixanol injection on December 17 for both intravenous and intra-arterial administration With the launch of Iodixanol ...

Fresenius Kabi's ustekinumab biosimilar Otulfi ™ is now commercially available for both subcutaneous and intravenous formulations With this launch, Fresenius Kabi Canada's immunology biosimilar ...

Fresenius Kabi's tocilizumab biosimilar Tyenne ® is the first and only tocilizumab biosimilar to be launched in Canada and is now commercially available for both subcutaneous and intravenous ...

With this launch, Fresenius Kabi Canada's immunology biosimilar portfolio is further expanding, offering more treatment options for patients with chronic autoimmune conditions Tyenne ® is ...

--(BUSINESS WIRE)--Fresenius Kabi, an operating company of Fresenius, announced today that Epinephrine Injection, USP, is now available in the United States as the first generic version of ...

Cellular Origins and Fresenius Kabi, an operating company of Fresenius, announce today they have signed a development agreement that leverages each company’s expertise in cell and gene therapies ...

Within the US glucagon injection market, Amphastar is currently operating in an effective duopoly with Fresenius KABI as the other ... ganirelix and vasopressin." - Q3 '23 Earnings Call As a ...

Fresenius Kabi Philippines, Inc.—a global healthcare company that focuses on lifesaving medicines for infusion, transfusion, and clinical nutrition welcomed the first quarter of the year with ...